drugset
drugset / Trial / NCT06323213

Efficacy and Safety Study of 610 in Patients With Severe Asthma

NCT06323213 ↗

Phase 3 Recruiting 480 enrolled Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

The primary objective of the study is to evaluate the efficacy and safety of 610 in Chinese adults with severe asthma.

Timeline

Start
2024-06-24
Primary completion
2027-02
Completion
2027-09

Drugs

EvaluationDrugModalityDoseRoute
Subject 610 Unknown — Subcutaneous

Indications

asthma